Clinical Trial

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study will investigate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 in participants with advanced or metastatic Microsatellite Stable (MSS)/Microsatellite Instability Low (MSI-L) Colorectal Cancer
Protocol Amendment History 1 change
notable Trial sites expanded: 4 -> 7 locations 2026-05-30
Trial Details
NCT Number NCT07321106
Lead Sponsor Cartography Biosciences
Conditions Colorectal Cancer, Colorectal Cancer (CRC), Colorectal (Colon or Rectal) Cancer, CRC, Metastatic Colon Cancer, Colon Cancer, Advanced Colorectal Cancer
Enrollment 80 participants
Start Date 2026-01-15
Primary Completion 2029-04 (estimated)
Study Completion 2029-10 (estimated)
Updated on ClinicalTrials.gov 2026-07-28